Title:
改良された腫瘍反応性Ｔ細胞の選択
Document Type and Number:
Japanese Patent JP2022512915
Kind Code:
A
Abstract:
本発明は、ＰＤ－１発現に基づいてＴＩＬを事前選択するための方法、ならびに増強された腫瘍特異的致死能力（例えば、増強された細胞傷害性）を有する治療用ＴＩＬ集団を産生するためにそれらの事前選択されたＰＤ－１陽性ＴＩＬを増殖するための方法を提供する。【選択図】図１７１
Inventors:
Simpson-Abelson, Michelle
Natarajan, Irvind
Chartier-Kurt, Cecil
Paulson, Matt
Natarajan, Irvind
Chartier-Kurt, Cecil
Paulson, Matt
Application Number:
JP2021524032A
Publication Date:
February 07, 2022
Filing Date:
November 04, 2019
Export Citation:
Assignee:
Iovance Biotherapeutics, Incorporated
International Classes:
C12N5/078; A61K35/17; A61K38/20; A61K39/395; A61P35/00; A61P37/04; A61P43/00; C12N1/00
Foreign References:
| WO2018182817A1 | 2018-10-04 | |||
| WO2018081473A1 | 2018-05-03 | |||
| WO2017070042A1 | 2017-04-27 | |||
| US20120244133A1 | 2012-09-27 |
Other References:
MICHELLE R. SIMPSON ABELSON ET AL.: "The T cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor", SITC 32ND ANNUAL MEETING, vol. P357, JPN6022041646, 8 November 2017 (2017-11-08), ISSN: 0005224293
GROS, ALENA ET AL.: "PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors", J CLIN INVEST., vol. 124(5): 2246-2259, JPN6023052380, 2014, ISSN: 0005224294
GROS, ALENA ET AL.: "PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors", J CLIN INVEST., vol. 124(5): 2246-2259, JPN6023052380, 2014, ISSN: 0005224294
Attorney, Agent or Firm:
Yoshiyuki Inaba
Toshifumi Onuki
Akihiko Eguchi
Kazuhiko Naito
Toshifumi Onuki
Akihiko Eguchi
Kazuhiko Naito